Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | DRD5 | P21918 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4687609 | 0.99 | DRD2 (0.52) | DRD2DRD3ADRA1AHTR7POLB | |
| SCHEMBL4687764 | 0.92 | DRD2 (0.51) | DRD2DRD3ADRA1AHTR7POLB | |
| SCHEMBL4688108 | 0.90 | DRD2 (0.55) | DRD2DRD3ADRA1AHTR7SMN1; SMN2 | |
| SCHEMBL4684447 | 0.89 | DRD2 (0.54) | DRD2DRD3ADRA1AHTR7SMN1; SMN2 | |
| SCHEMBL4684299 | 0.89 | DRD2 (0.54) | DRD2DRD3ADRA1AHTR7SMN1; SMN2 | |
| SCHEMBL4683575 | 0.86 | DRD2 (0.53) | DRD2DRD3ADRA1AHTR7POLB | |
| SCHEMBL4687021 | 0.86 | DRD2 (0.63) | DRD2DRD3ADRA1AHTR7SMN1; SMN2 | |
| SCHEMBL4688657 | 0.86 | HTR7 (0.55) | DRD2DRD3ADRA1AHTR7SMN1; SMN2 | |
| SCHEMBL4684376 | 0.86 | DRD2 (0.55) | DRD2DRD3ADRA1AHTR7POLB | |
| Hydrochloric Acid SCHEMBL4690031 | 0.86 | DRD2 (0.53) | DRD2DRD3ADRA1AHTR7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | claimed |
| EP-1828125-B1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET SOC CIV (FR) | 2008-04-09 | — | — | EP | claimed |
| EP-1828125-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2007-09-05 | — | — | EP | claimed |
| WO-2006058993-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANDS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2006-06-08 | — | — | WO | claimed |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
| EP-1828125-B1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET SOC CIV (FR) | 2008-04-09 | — | — | EP | disclosed |
| EP-1828125-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006058993-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANDS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006058993-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANDS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | SLC6A3, ADRB3, PRLHR | DRD2 8/4885DRD3 4/4885ADRA1A 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.